These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study. Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997 [TBL] [Abstract][Full Text] [Related]
3. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor. Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906 [TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733 [TBL] [Abstract][Full Text] [Related]
5. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992 [TBL] [Abstract][Full Text] [Related]
6. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy. O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383 [TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study. Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175 [TBL] [Abstract][Full Text] [Related]
8. The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer. Setti M; Bignardi D; Ballestrero A; Ferrando F; Musselli C; Blanchi S; Basso M; Bosco O; Balleari E; Patrone F; Indiveri F Cancer Immunol Immunother; 1999 Sep; 48(6):287-96. PubMed ID: 10473803 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386 [TBL] [Abstract][Full Text] [Related]
11. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. Chi KH; Chen CH; Chan WK; Chow KC; Chen SY; Yen SH; Chao JY; Chang CY; Chen KY J Clin Oncol; 1995 Oct; 13(10):2620-8. PubMed ID: 7595716 [TBL] [Abstract][Full Text] [Related]
12. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes. Singh SM; Sone S; Inamura N; Ogura T Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733 [TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554 [TBL] [Abstract][Full Text] [Related]
14. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial. Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854 [TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950 [TBL] [Abstract][Full Text] [Related]
16. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma. Gill PS; Bernstein-Singer M; Espina BM; Rarick M; Magy F; Montgomery T; Berry MS; Levine A AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520 [TBL] [Abstract][Full Text] [Related]
17. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity. Liljefors M; Nilsson B; Mellstedt H; Frödin JE Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322 [TBL] [Abstract][Full Text] [Related]
18. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction. Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177 [TBL] [Abstract][Full Text] [Related]
19. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433 [TBL] [Abstract][Full Text] [Related]
20. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]